Healthcare provider consolidation continues to attract antitrust scrutiny. Practical implications for deal structure and regulatory engagement.
Healthcare M&A faces sustained antitrust attention, particularly in geographic markets where provider consolidation has been intensive. Transactional teams should integrate antitrust analysis early in deal evaluation, plan for HSR review timelines, and consider remedies that may be required to clear concerning transactions.